The latest market price of voclosporin in 2025 and reference drug purchase information in pharmacies in various regions

Voclosporin is a new type of immunosuppressant, mainly used for the treatment of systemic lupus erythematosus (SLE) accompanied by active lupus nephritis. By inhibiting T cell activation and inflammatory response, it improves renal function and reduces proteinuria levels, providing an innovative treatment option for patients. Due to its targeting mechanism and good efficacy, cyclosporine is clinically considered a new first-line drug for the treatment of lupus nephritis.

In the domestic market, as of2025, the original drug of cyclosporin has not yet been launched in China, so patients are temporarily unable to obtain the drug directly through domestic hospitals or pharmacies. At the same time, the drug has not been included in the domestic medical insurance catalog, and the relevant reimbursement policy has not yet been introduced. If domestic patients have urgent drug needs, they can currently only focus on clinical trials or wait for official marketing approval to ensure that the sources of drugs are legal and the quality is reliable.

In overseas markets, cyclosporin has been launched in Europe. The European version of the original drug has a specification of 7.9mg*180 tablets. Each box sells for about 16,000 yuan (the price may fluctuate due to exchange rates and regional differences). Currently, there are no generic versions of this drug on the market, so overseas markets mainly rely on the supply of original drugs. When patients purchase drugs overseas, they need to choose regular pharmacies or authorized medical channels and avoid obtaining drugs through informal channels to ensure efficacy and safety.

In general, cyclosporine has not yet been opened in the domestic market in 2025, and patients still need to wait for the market launch and the clarification of medical insurance policies. Overseas European original drugs are more expensive and cannot be replaced by generic drugs. Patients must strictly follow the doctor's guidance for individualized treatment based on their own condition, financial ability and medical channels before use. At the same time, with the advancement of domestic drug approval and medical insurance policies, cyclosporine is expected to provide a safe, effective and accessible treatment option for more patients with lupus nephritis in the future.

Reference materials:https://www.drugs.com/